Naslov
Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases

Autori
Bašić-Kinda, Sandra ; Mišura Jakobac, Karla ; Sinčić-Petričević, Jasminka ; Deak, Dajana ; Vodanović, Marijo ; Jakić-Bubalo, Marinka ; Mitrović, Zdravko ; Grubešić, Aron ; Dreta, Barbara ; Županić Krmek, Dubravka ; Coha, Božena ; Radić-Krišto, Delfa ; Aurer, Igor

Izvornik
Croatian medical journal (0353-9504) 62 (2021), 5; 455-463

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
mantle cell lymphoma ; rituximab ; bendamustine ; autologous stem cell transplantation ; cytarabine

Sažetak
Aim To compare the outcomes of Croatian patients with mantle cell lymphoma (MCL) who started treatment in 2007 and 2008 (historical cohort) and of those who started treatment between 2015 and 2017 (recent cohort). Methods The historical cohort consisted of 40 patients who started treatment with rituximab in 2007 and 2008. Data on the recent cohort, consisting of 89 patients, were collected retrospectively from the electronic databases of Croatian hospitals with hematology units. Demographic characteristics and data on induction regimens, autologous stem cell transplantation (ASCT), and rituximab maintenance in the first remission, event-free survival (EFS), and overall survival (OS) were available for both cohorts, and data on cell morphology, mantle cell international prognostic index (MIPI), and Ki67 expression only for the recent cohort. Results The recent cohort had significantly better two-year EFS and OS (EFS 58% vs 40%, P = 0.014 ; OS 80% vs 56%, P = 0.009), especially in patients below 65. In univariate analysis, induction regimen, ASCT, and maintenance were significant prognostic factors for EFS and the former two for OS. In the multivariate analysis, only ASCT remained significant. Bendamustine + rituximab (BR) induction improved the outcomes of non- transplantable patients over R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, steroid). Blastoid morphology and high MIPI were adverse prognostic factors for EFS and OS. Conclusion In the last decade, the outcome of newly diagnosed MCL patients improved. ASCT in the first remission was the main contributor in transplantable patients and BR in non- transplantable. Regularly updated national guidelines may help in a timely adoption of new treatments, thus improving the results.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA